Cooperative Agreement U01CA294674
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$643K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
New Orleans, LA 70118, USA
Similar Awards
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), aims to develop a point-of-care HPV DNA test for cervical cancer screening in Mozambique. The total award is $585,943, with a performance period from September 1, 2024 to August 31, 2029. The key objectives are to: 1) Adapt existing extraction-free, multiplexed, isothermal nucleic acid amplification assays to detect 8...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to develop and evaluate an evidence-based, behavioral cervical cancer screening intervention for women living with HIV in Ghana. The $511,959 award to Baylor University will fund a hybrid effectiveness-implementation trial to integrate and scale up a home-based HPV self-sampling and communication model intervention called HOPE. The project seeks to...
The National Cancer Institute (NCI) awarded a 5-year, $706,365 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to The Trustees of Columbia University in the City of New York to implement the WHO-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project aims to sustain implementation of the ISTAR approach and generate new data to inform effective and equitable...
The National Cancer Institute (NCI) awarded a 5-year, $629,068 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to Albert Einstein College of Medicine to conduct an implementation study of integrated human papillomavirus (HPV) self-sampling in HIV care centers in Ethiopia. The study aims to leverage the Project ECHO (Extension for Community Healthcare Outcomes) virtual learning platform to promote experience sharing and technical assistance across 5 hospitals to improve...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,837,497 to New York University to conduct the KUPEWA project. The project aims to (A) identify optimal implementation strategies for increasing clinician recommendation of HPV vaccination for girls and young women aged 9-24 living with HIV in Malawi, (B) refine these strategies based on implementability, and (C) identify strategies that are effective,...
The Cooperative Agreement awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $1,245,116 to Emory University from September 1, 2024 to August 31, 2029. The project, "Enhancing Cervical Cancer Screening and Treatment in Women Living with HIV in Kenya (ENHANCE Linkage)", aims to adapt and test implementation strategies to expand HIV care to screen for and treat early precancerous cervical cancer lesions in a...
This $753,446 Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) aims to adapt and test an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations: urban inner city Blacks/Haitians in Boston, Hispanic immigrants in Florida, and Hawaiian Natives/Pacific Islanders in Hawaii. The intervention combines education and quality improvement methods using a mechanism called Performance...
This federal Project Grant award, totaling $477,869.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant aims to develop tailored, multilevel cervical cancer interventions for ethnically diverse Black women, including African American women and Black African immigrant women. The key objectives are to: 1) identify multilevel determinants of routine cervical cancer screening and follow-up adherence among these populations,...
The National Cancer Institute (NCI) awarded a $1,729,890 Cooperative Agreement (CFDA 93.395 - Cancer Treatment Research) to Washington University to develop and validate a new 3D skin imaging technology, SkinScan3D, for improved monitoring of Kaposi Sarcoma (KS) treatment response in East Africa. The project has three main components: Refining the SkinScan3D device and usage protocols through human-centered design workshops with clinicians and patients in Uganda and Kenya to ensure the...
This $5,121,760.00 Cooperative Agreement award from the Centers for Disease Control and Prevention's (CDC) Global AIDS program (CFDA 93.067) supports comprehensive HIV/AIDS prevention, care, and treatment services in Nampula Province, Mozambique. The primary awardee, Servico Provincial De Saude De Nampula, a provincial health service organization in Mozambique, will use the funding over the 5-year project period from September 2024 to September 2029 to implement technical assistance, capacity...